secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001213900-22-024098
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics Q1 2022 net loss narrows to $10.8M; cash $118.5M funds into mid-2024
--------------------------------------------------------------------------------

- Net loss of $10.8M ($0.96/share) versus $13.5M ($1.20/share) in Q1 2021.
- Cash and equivalents $118.5M as of March 31, 2022; expected to fund operations into mid-2024.
- Phase 1 ADVANCED-1 trial of TARA-002 for NMIBC first patient dosed in March 2022.
- FDA preliminary guidance received for TARA-002 in lymphatic malformations; Phase 2 trial planning underway.
- U.S. patent issued for IV Choline Chloride composition with term expiring in 2041.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022024098/0001213900-22-024098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022024098/ea159335-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-024098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer